Inhibition of the 26 S proteasome by polyubiquitin chains synthesized to have defined lengths.
Ubiquitin is a covalent signal that targets cellular proteins to the 26 S proteasome. Multiple ubiquitins can be ligated together through the formation of isopeptide bonds between Lys48 and Gly76 of successive ubiquitins. Such a polyubiquitin chain constitutes a highly effective proteolytic targeting signal, but its mode of interaction with the proteasome is not well understood. Experiments to address this issue have been limited by difficulties in preparing useful quantities of polyubiquitin chains of uniform length. We report a simple method for large scale synthesis of Lys48-linked polyubiquitin chains of defined length. In the first round of synthesis, two ubiquitin derivatives (K48C-ubiquitin and Asp77-ubiquitin) were used as substrates for the well characterized ubiquitin-conjugating enzyme E2-25K. Diubiquitin blocked at the nascent proximal and distal chain termini was obtained in quantitative yield. Appropriately deblocked chains were then combined to synthesize higher order chains (tetramer and octamer in the present study). Deblocking was achieved either enzymatically (proximal terminus) or by chemical alkylation (distal terminus). Chains synthesized by this method were used to obtain the first quantitative information concerning the influence of polyubiquitin chain length on binding to the 26 S proteasome; this was done through comparison of different length (unanchored) polyubiquitin chains as inhibitors of ubiquitin-conjugate degradation. K0.5 was found to decrease approximately 90-fold, from 430 to 4.8 microM, as the chain was lengthened from two to eight ubiquitins. The implications of these results for the molecular basis of chain recognition are discussed.
Piotrowski
J
J
Department of Biochemistry, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA.
Beal
R
R
Hoffman
L
L
Wilkinson
K D
KD
Cohen
R E
RE
Pickart
C M
CM
D000478:Alkylation; D001704:Biopolymers / Q000096:biosynthesis / Q000378:metabolism / Q000494:pharmacology*; D003546:Cysteine Endopeptidases / Q000187:drug effects* / Q000378:metabolism; D015853:Cysteine Proteinase Inhibitors / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D009097:Multienzyme Complexes / Q000187:drug effects* / Q000378:metabolism; D025821:Polyubiquitin; D046988:Proteasome Endopeptidase Complex; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D014452:Ubiquitins / Q000096:biosynthesis / Q000378:metabolism / Q000494:pharmacology*
D001704:Biopolymers; D015853:Cysteine Proteinase Inhibitors; D009097:Multienzyme Complexes; D014452:Ubiquitins; D025821:Polyubiquitin; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex